CytomX Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $512.32M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | $1.40M | $-0.09 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | $10.30M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 16, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | $6.00M | $-0.09 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | $18.70M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | Before market open | $50.90M | $0.27 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 6, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | $33.40M | $0.07 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 11, 2024 | After market close | – | – | – |
Press releases
Announcements CytomX Therapeutics filed with the SEC
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides
Results of operations · EX-99.1 to Form 8-K
CytomX Therapeutics Announces Q1 2026 Financial Results and Provides
Results of operations · EX-99.1 to Form 8-K
CytomX Therapeutics Announces 2025 Financial Results and Provides
Results of operations · EX-99.1 to Form 8-K
CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides
Results of operations · EX-99.1 to Form 8-K
CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides
Results of operations · EX-99.1 to Form 8-K
CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides
Results of operations · Other events · EX-99.1 to Form 8-K
CytomX Therapeutics Announces 2024 Financial Results and Provides
Results of operations · EX-99.1 to Form 8-K
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for
Other events · EX-99.1 to Form 8-K
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99 to Form 8-K
CytomX Therapeutics Reports Full Year 2022 Financial Results
Results of operations · EX-99 to Form 8-K
CytomX Therapeutics Reports Third Quarter 2022 Financial Results and
Results of operations · EX-99.1 to Form 8-K
CytomX Therapeutics Reports Second Quarter 2022 Financial Results and
Results of operations · EX-99.1 to Form 8-K
CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update
Results of operations · EX-99.1 to Form 8-K